Paper Details

  1. Home
  2. Paper Details

Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility.

Author: AzizQ, BoundoukiG, BroadJ, De MaeyerJ H, KnowlesC H, KungV W S, SangerG J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Donepezil, an AChE inhibitor, and prucalopride, a 5-HT4 receptor agonist, show promising potential for treating acute colonic pseudo-obstruction. Their individual and combined effects on human colon suggest a synergistic approach that could minimize side effects and improve efficacy.
Paper Details　
Original Abstract of the Article :
Cholinesterase inhibitors such as neostigmine are used for acute colonic pseudo-obstruction, but cardio-bronchial side-effects limit use. To minimize side-effects, lower doses could be combined with a 5-HT4 receptor agonist, which also facilitates intestinal cholinergic activity. However, safety con...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838700/

データ提供：米国国立医学図書館（NLM）

Donepezil and Prucalopride: A Potential Oasis for Severe Intestinal Dysmotility

Intestinal dysmotility is a condition that disrupts the normal movement of food through the digestive tract. It's like a sandstorm in your gut, causing discomfort and affecting digestion. This study examines the potential for combining donepezil, a cholinesterase inhibitor used for Alzheimer's disease, and prucalopride, a 5-HT4 receptor agonist, to treat severe intestinal dysmotility. The researchers explore the individual and synergistic effects of these drugs on human colon tissue. Their findings suggest that this combination therapy could be a promising oasis for patients with severe intestinal dysmotility. They found that both donepezil and prucalopride have a positive impact on colonic motility, and the combination of the two drugs may be even more effective. This suggests that this combination therapy could be a valuable tool for managing severe intestinal dysmotility, potentially offering relief to patients struggling with this debilitating condition.

A New Hope for Severe Intestinal Dysmotility

This study offers hope for patients with severe intestinal dysmotility. The combination of donepezil and prucalopride may offer a new and potentially more effective way to manage this condition.

Navigating the Desert of Digestive Health

This research underscores the complexity of intestinal dysmotility and the need for innovative treatments. It highlights the potential of combining different drugs to achieve better outcomes for patients with severe intestinal dysmotility.

Dr.Camel's Conclusion

This study is like a refreshing oasis in the desert of intestinal dysmotility. It explores the potential of a novel combination therapy that could offer a new path to relief for patients with this challenging condition. While more research is needed, this study offers a glimmer of hope for those struggling with severe intestinal dysmotility.

Date :
  1. Date Completed 2014-11-06
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

24032987

DOI: Digital Object Identifier

PMC3838700

Related Literature

Article Analysis
・Side Effects of prucalopride
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.